These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

129 related items for PubMed ID: 9599596

  • 1. Dolasetron for prevention of nausea and vomiting due to cancer chemotherapy.
    Med Lett Drugs Ther; 1998 May 08; 40(1026):53-4. PubMed ID: 9599596
    [No Abstract] [Full Text] [Related]

  • 2. Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.
    Rubenstein EB.
    Clin Adv Hematol Oncol; 2004 May 08; 2(5):284-9. PubMed ID: 16163194
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. A double-blind, multicentre comparison of intravenous dolasetron mesilate and metoclopramide in the prevention of nausea and vomiting in cancer patients receiving high-dose cisplatin chemotherapy.
    Chevallier B, Cappelaere P, Splinter T, Fabbro M, Wendling JL, Cals L, Catimel G, Giovannini M, Khayat D, Bastit P, Claverie N.
    Support Care Cancer; 1997 Jan 08; 5(1):22-30. PubMed ID: 9010986
    [Abstract] [Full Text] [Related]

  • 5. Single-dose, placebo-controlled, phase I study of oral dolasetron.
    Dixon RM, Cramer M, Shah AK, Whitmore J, Benedict CR, Hahne WF.
    Pharmacotherapy; 1996 Jan 08; 16(2):245-52. PubMed ID: 8820468
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron.
    Eisenberg P, Figueroa-Vadillo J, Zamora R, Charu V, Hajdenberg J, Cartmell A, Macciocchi A, Grunberg S, 99-04 Palonosetron Study Group.
    Cancer; 2003 Dec 01; 98(11):2473-82. PubMed ID: 14635083
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Intravenous dolasetron mesilate in the prevention of postoperative nausea and vomiting in females undergoing gynecological surgery.
    Diemunsch P, D'Hollander A, Paxton L, Schoeffler P, Wessel P, Navé S, Brown RA, Hahne WF.
    J Clin Anesth; 1997 Aug 01; 9(5):365-73. PubMed ID: 9257201
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Relative efficacy of ondansetron, granisetron, dolasetron and palonosetron in controlling acute nausea and vomiting associated with platinum-based chemotherapy.
    Hamadani M, Awab A, Chaudhary L, Tfayli A.
    J Oncol Pharm Pract; 2006 Jun 01; 12(2):67-8. PubMed ID: 16984743
    [No Abstract] [Full Text] [Related]

  • 12. Dose-ranging evaluation of the serotonin antagonist dolasetron mesylate in patients receiving high-dose cisplatin.
    Kris MG, Grunberg SM, Gralla RJ, Baltzer L, Zaretsky SA, Lifsey D, Tyson LB, Schmidt L, Hahne WF.
    J Clin Oncol; 1994 May 01; 12(5):1045-9. PubMed ID: 8164028
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Are all 5-HT3 receptor antagonists the same?
    McNulty R.
    J Natl Compr Canc Netw; 2007 Jan 01; 5(1):35-43. PubMed ID: 17239324
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.